SOSharifah Faridah Syed Omar

Sharifah Faridah Syed Omar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sharifah Faridah Syed Omar has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response Letter to the Letter to the Editor by Dr. Pallab K. Maulik

    by Say Hiang Lim, Yin Cheng Lim, Rafdzah Ahmad Zaki, Bushra Megat Johari, Chung Yuan Chang, Sharifah Faridah Syed Omar, Amirah Azzeri, Maznah Dahlui, Adeeba Kamarulzaman

  • Open Access

    Core Outcome Measurement Set for Clinical Trials in Dengue: An International Delphi Consensus Study ‘DEN-CORE’

    by Sophie Yacoub, Anastasia Demidova, Xin Hui S Chan, Ali Ajam, Dina Baimukhambetova, Andreij Horn, Evgeniia Kakotkina, Mark Kosenko, Aigun Mursalova, Jennifer Ilo Van Nuil, et al.

    Dengue, caused by any one of four distinct virus serotypes, is the most rapidly spreading mosquito-borne viral disease worldwide. It is a primary arboviral infection with increasing global incidence, driven by climate change, urbanisation, and the expanding range of Aedes mosquito vectors. Despite growing research interest, outcome and measurement instrument heterogeneity in dengue clinical trials remains high, limiting comparability and evidence synthesis. This project aimed to develop a globally relevant Core Outcome Measurement Set (COMS) for use in dengue clinical trials through international consensus.This consensus study followed COMET and COS-STAD guidelines and was conducted in two phases. Phase I focused on developing a core outcome set (COS) through six steps: (1) a systematic literature review; (2) qualitative interviews with people with lived experience of dengue; (3) review by the management group and steering committee; (4) a two-round modified Delphi survey and structured online consensus meetings to finalise the COS for ‘hospitalised’ and ‘early’ stages of dengue. Input from critical care experts informed recommendations for the ‘ICU/HDU’ COS. Phase II involved: (5) targeted review of outcome measurement instruments; and (6) a hybrid international consensus workshop to finalise the COMS.The agreed COMS for ‘hospitalised’ dengue included seven outcomes; the ‘early’ COS includes these plus four more. For critical care trials, use of existing ICU-specific COS was recommended. Unified definitions were developed for nine clinician-reported outcomes.The DEN-CORE COMS provides a consensus-based framework for harmonising outcome selection and measurement in dengue trials, improving comparability and supporting policy and clinical decision-making.

  • Open Access

    Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial

    by Daniel Vincent O'HAra, Abhinav Bassi, Arlen Wilcox, Vivekanand Jha, Vinay Rathore, Sanjay D'CRuz, Thomas L Snelling, Mark Jones, James Totterdell, Ashpak Bangi, et al.

    Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19. Design Prospective, multicentre, double-blind, placebo-controlled trial. Setting Ten acute care hospitals in India. Participants Adults Intervention DMX-200 120 mg two times per day, or placebo, on background of titratable candesartan commencing at 4 mg two times per day, for 28 days. Main outcome measures The primary endpoint was COVID-19 disease severity on a modified WHO Clinical Progression Scale (WHO scale) on day 14. Secondary outcomes included the WHO scale at days 28, 60, 90 and 180; intensive care unit (ICU) admission, respiratory failure or death within 28 days; length of hospitalisation; and requirement for ventilatory support or dialysis. Results Between December 2021 and August 2022, 518 people were screened, with 49 randomised to DMX-200 or placebo on a background of candesartan. The study was terminated early due to recruitment barriers, including an external requirement to restrict enrolment to adults Conclusion Due to recruitment barriers, the study was unable to determine whether DMX-200 improves clinical outcomes in people with COVID-19. Trial registration number ClinicalTrials.gov NCT05122182.


  • Open Access

    Effect of Long COVID on Work Performance and Annual Monetary Loss Among Infected Health Care Workers at a Tertiary Hospital in Malaysia

    by Say Hiang Lim, Yin Cheng DrPH Lim, Rafdzah Ahmad DrPH Zaki, Bushra Megat Mrcp Johari, Chung Yuan Chang, Sharifah Faridah Syed MInMed Omar, Amirah Azzeri, Maznah Dahlui, Adeeba Fracp Kamarulzaman

    Objective: The aim of the study is to assess and compare the work performance loss (absenteeism and presenteeism) and the estimated annual monetary loss among health care workers with and without long COVID. Methods: A retrospective cohort study was conducted between October 2022 and April 2024 using an online questionnaire. The shortened version of the Health and Work Performance Questionnaire was used to estimate the work performance effect among health care workers with a history of COVID-19 infection. Results: Health care workers with long COVID have a significantly lower absolute presenteeism and higher annual monetary loss of presenteeism. The mean annual monetary loss of presenteeism was higher in those with long COVID (MYR 10,866.61) compared to those without (MYR 9243.85). Conclusions: Implementing supportive work strategies in hospital settings is recommended to reduce absolute presenteeism and the annual monetary loss of presenteeism.


  • Open Access

    Propagation of a hospital-associated cluster of COVID-19 in Malaysia

    by Diane Woei-Quan Chong, Vivek Jason Jayaraj, Chiu-Wan Ng, I-Ching Sam, Mas Ayu Said, Rafdzah Ahmad Zaki, Noran Naqiah Hairi, Nik Daliana Nik Farid, Victor Chee-Wai Hoe, Marzuki Isahak, et al.

    Background: Hospitals are vulnerable to COVID-19 outbreaks. Intrahospital transmission of the disease is a threat to the healthcare systems as it increases morbidity and mortality among patients. It is imperative to deepen our understanding of transmission events in hospital-associated cases of COVID-19 for timely implementation of infection prevention and control measures in the hospital in avoiding future outbreaks. We examined the use of epidemiological case investigation combined with whole genome sequencing of cases to investigate and manage a hospital-associated cluster of COVID-19 cases. Methods: An epidemiological investigation was conducted in a University Hospital in Malaysia from 23 March to 22 April 2020. Contact tracing, risk assessment, testing, symptom surveillance, and outbreak management were conducted following the diagnosis of a healthcare worker with SARS-CoV-2 by real-time PCR. These findings were complemented by whole genome sequencing analysis of a subset of positive cases. Results: The index case was symptomatic but did not fulfill the initial epidemiological criteria for routine screening. Contact tracing suggested epidemiological linkages of 38 cases with COVID-19. Phylogenetic analysis excluded four of these cases. This cluster included 34 cases comprising ten healthcare worker-cases, nine patient-cases, and 15 community-cases. The epidemic curve demonstrated initial intrahospital transmission that propagated into the community. The estimated median incubation period was 4.7 days (95% CI: 3.5–6.4), and the serial interval was 5.3 days (95% CI: 4.3–6.5). Conclusion: The study demonstrated the contribution of integrating epidemiological investigation and whole genome sequencing in understanding disease transmission in the hospital setting. Contact tracing, risk assessment, testing, and symptom surveillance remain imperative in resource-limited settings to identify and isolate cases, thereby controlling COVID-19 outbreaks. The use of whole genome sequencing complements field investigation findings in clarifying transmission networks. The safety of a hospital population during this COVID-19 pandemic may be secured with a multidisciplinary approach, good infection control measures, effective preparedness and response plan, and individual-level compliance among the hospital population.


  • Open Access

    Case report : Actinomyces naeslundii complicating preterm labour in a trisomy-21 pregnancy

    by Hang-Cheng Ong, Albert Chuan-Kai Ling, Doris Sin-Wen Ng, Rong-Xiang Ng, Pui-Li Wong, Sharifah Faridah Syed Omar


  • Open Access

    SARS-CoV-2 lineage B.6 was the major contributor to early pandemic transmission in Malaysia

    by Yoong Min Chong, I-Ching Sam, Jennifer Chong, Maria Kahar Bador, Sasheela Ponnampalavanar, Sharifah Faridah Syed Omar, Adeeba Kamarulzaman, Vijayan Munusamy, Chee Kuan Wong, Fadhil Hadi Jamaluddin, et al.

    Malaysia had 10,219 confirmed cases of COVID-19 as of September 20, 2020. About 33% were associated with a Tablighi Jamaat religious mass gathering held in Kuala Lumpur between February 27 and March 3, 2020, which drove community transmission during Malaysia’s second wave. We analysed genome sequences of SARS-CoV-2 from Malaysia to better understand the molecular epidemiology and spread. We obtained 58 SARS-CoV-2 whole genome sequences from patients in Kuala Lumpur and performed phylogenetic analyses on these and a further 57 Malaysian sequences available in the GISAID database. Nine different SARS-CoV-2 lineages (A, B, B.1, B.1.1, B.1.1.1, B.1.36, B.2, B.3 and B.6) were detected in Malaysia. The B.6 lineage was first reported a week after the Tablighi mass gathering and became predominant (65.2%) despite being relatively rare (1.4%) globally. Direct epidemiological links between lineage B.6 viruses and the mass gathering were identified. Increases in reported total cases, Tablighi-associated cases, and community-acquired B.6 lineage strains were temporally linked. Non-B.6 lineages were mainly travel-associated and showed limited onward transmission. There were also temporally correlated increases in B.6 sequences in other Southeast Asian countries, India and Australia, linked to participants returning from this event. Over 95% of global B.6 sequences originated from Asia Pacific. We also report a nsp3-C6310A substitution found in 47.3% of global B.6 sequences which was associated with reduced sensitivity using a commercial diagnostic real-time PCR assay. Lineage B.6 became the predominant cause of community transmission in Malaysia after likely introduction during a religious mass gathering. This event also contributed to spikes of lineage B.6 in other countries in the Asia-Pacific. Mass gatherings can be significant causes of local and global spread of COVID-19. Shared genomic surveillance can be used to identify SARS-CoV-2 transmission chains to aid prevention and control, and to monitor diagnostic molecular assays. Clinical Trial Registration: COVID-19 paper.


  • Open Access

    A retrospective analysis of the care cascades for non‐communicable disease and mental health among people living with HIV at a tertiary‐care centre in Malaysia: opportunities to identify gaps and optimize care

    by Chong Meng Li, Fong Jie Ying, Dhevann Raj, Wong Pui Li, Anjanna Kukreja, Sharifah Fs Omar, Adeeba Kamarulzaman, Reena Rajasuriar

    Introduction: The rapidly growing epidemic of non‐communicable diseases (NCDs) including mental health among aging people living with HIV (PLWH) has put a significant strain on the provision of health services in many HIV clinics globally. We constructed care cascades for specific NCDs and mental health among PLWH attending our centre to identify potential areas for programmatic improvement.Methods: This was a follow‐up study of participants recruited in the Malaysian HIV & Aging study (MHIVA) from 2014 to 2016 at the University Malaya Medical Centre (n = 336). PLWH on suppressive antiretroviral therapy (ART) for a minimum of 12 months were invited to participate. At study entry, all participants underwent screening for diabetes (DM), hypertension (HTN) and dyslipidaemia; and completed assessments using the depression, anxiety and stress scale (DASS‐21). Screening results were recorded in medical charts and clinical management provided as per standard of care. A subsequent review of medical records was performed at 24 months following study completion among participants who remained on active follow‐up. Treatment pathways for NCD treatment and psychiatric referrals were assessed based on local practice guidelines to construct the care cascade.Results: A total of 329 participants (median age = 43 years, 83% male, 100% on ART) completed follow‐up at 24 months. The prevalence of diabetes was 13%, dyslipidaemia 88% and hypertension 44%, whereas 23% presented with severe/extremely severe symptoms of depression, anxiety and/or stress. More than 50% of participants with dyslipidaemia and hypertension were not diagnosed until study screening, whereas over 80% with prevalent psychiatric symptoms were not previously recognized clinically. Suboptimal control of fasting lipids, sugar and blood pressure were found in the majority of participants despite optimal HIV treatment outcomes maintained over this same period. Only 32% of participants with severe/extremely severe mental health symptoms received psychiatric referrals and 83% of these attended their psychiatry clinic appointments.Conclusions: Systematic screening must be introduced to identify NCDs and mental health issues among PLWH followed by proper linkage and referrals for management of screen‐positive cases. Assessment of factors associated with attrition at each step of the care cascade is critically needed to improve health outcomes in our aging patients.


  • Open Access

    SARS-CoV-2 lineage B.6 is the major contributor to transmission in Malaysia

    by Yoong Min Chong, I-Ching Sam, Jennifer Chong, Maria Kahar Bador, Sasheela Ponnampalavanar, Sharifah Faridah Syed Omar, Adeeba Kamarulzaman, Vijayan Munusamy, Chee Kuan Wong, Fadhil Hadi Jamaluddin, et al.

    Background: As of June 30, 2020, Malaysia had confirmed 8,639 cases of COVID-19. About 39% of these were associated with a religious mass gathering event held in Kuala Lumpur between February 27 and March 1, 2020, which drove community transmission during Malaysia’s main wave. We analysed genome sequences of SARS-CoV-2 from Malaysia to understand the molecular epidemiology. Methods: We obtained whole genome sequences of SARS-CoV-2 from 58 COVID-19 patients in Kuala Lumpur, Malaysia, and performed phylogenetic analyses on these and a further 50 Malaysian sequences available in the GISAID database. Malaysian lineage B.6 sequences were further analysed with all available worldwide lineage B.6 sequences. Results: Nine different SARS-CoV-2 lineages (A, B, B.1, B.1.1, B.1.1.1, B.1.36, B.2, B.3 and B.6) were detected in Malaysia. The B.6 lineage was first reported a week after the mass gathering and became predominant (63%) despite being relatively rare (1.4%) among available global sequences. Increases in reported cases and community-acquired B.6 lineage strains were temporally linked. Non-B.6 lineages were mainly associated with travel and showed limited onward transmission. There were also temporally-correlated increases in B.6 sequences in other Southeast Asian countries, India and Australia, linked to participants returning from this event. We also report the presence of a nsp3-C6310A substitution found in 40.5% of global B.6 sequences which has associated with reduced sensitivity in a commercial assay. Conclusion: Lineage B.6 became the predominant cause of community transmission in Malaysia after likely introduction during a religious mass gathering. This event also contributed to spikes of lineage B.6 in other countries in the region. Author Summary: The COVID-19 pandemic in Malaysia was driven mainly by transmission following a religious mass gathering held in Kuala Lumpur at the end of February. To study the genetic epidemiology of SARS-CoV-2 in Malaysia, we analysed 50 available and 58 newly-generated Malaysian whole genome virus sequences. We found that lineage B.6, rare (1.4%) globally, first appeared after the mass gathering and became the most predominant (62.9%) in Malaysia. Increases in COVID-19 cases and locally-acquired B.6 strains were temporally linked. Non-B.6 viruses were mainly associated with travel and showed limited spread. Increases in B.6 viruses in Southeast Asian countries, India and Australia were linked to participants returning from this mass gathering. Altogether, 95.3% of global B.6 sequences originated in Asia or Australia. We also report a mutation in the virus nsP3 gene found in 40.5% of global B.6 sequences and associated with reduced detection by a commercial diagnostic test. In conclusion, the religious mass gathering in Kuala Lumpur was associated with the main wave of COVID-19 cases of predominantly B.6 lineage in Malaysia, and subsequent spread of B.6 viruses regionally. Genome sequence data provides valuable insight into virus spread and is important for monitoring continued accuracy of diagnostic kits.


  • Open Access

    Precursors to non-invasive clinical dengue screening: Multivariate signature analysis of in-vivo diffuse skin reflectance spectroscopy on febrile patients in Malaysia

    by Abdul Halim Poh, Faisal Rafiq Mahamd Adikan, Mahmoud Moghavvemi, Sharifah Faridah Syed Omar, Khadijah Poh, Mohamad Badrol Hisyam Mahyuddin, Grace Yan, Mohammad Aizuddin Azizah Ariffin, Sulaiman Wadi Harun

    Dengue diagnostics have come a long way. Attempts at breaking away from lab-oriented dengue detection, such as NS1 antigen, IgM or IgG antibodies detection have extensively received numerous coverage. As a result, rapid detection tests (RDTs) have started to gain inroads in medical practice. Rapid detection tests notwithstanding, analysis of blood serum is still a relatively complicated task. This includes the necessity of phlebotomy, centrifugation for blood serum, and other reagent-based tests. Therefore, a non-invasive method of dengue detection was considered. In this study, we present the utility of diffuse reflectance skin spectroscopy (bandwidth of 200-2500nm) on the forearm during the triaging period for dengue screening potential. This is performed with multivariate analysis of 240 triaged febrile/suspected dengue patients. The data is then scrutinized for its clinical validity to be included as either confirmed or probable dengue, or a control group. Based on discriminant analysis of several data normalization models, we can predict the patients’ clinical dengue-positivity at ranges of accuracy between ~93–98% depending on mode of the data, with a probably optimal sensitivity and specificity to the clinical diagnosis of ~89% and ~100% respectively. From the outcomes of this study, we recommend further trials with cautious optimism. With these findings, it is hoped that the elusive non-invasive detection of tropical diseases may gain platform in the near future.